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We characterized B cell infiltration of the spinal cord in a B cell-dependent spontaneous
model of central nervous system (CNS) autoimmunity that develops in a proportion of
mice with mutant T and B cell receptors specific for myelin oligodendrocyte glycoprotein.
We found that, while males are more likely to develop disease, females are more likely to
have a chronic rather than monophasic disease course. B cell infiltration of the spinal cord
was investigated by histology and FACs. CD4+ T cell infiltration was pervasive throughout
the white and in some cases gray matter. B cells were almost exclusively restricted to the
meninges, often in clusters reminiscent of those described in human multiple sclerosis.
These clusters were typically found adjacent to white matter lesions and their presence
was associated with a chronic disease course. Extensive investigation of these clusters
by histology did not identify features of lymphoid follicles, including organization of T
and B cells into separate zones, CD35+ follicular dendritic cells, or germinal centers.
The majority of cluster B cells were IgD+ with little evidence of class switch. Consistent
with this, B cells isolated from the spinal cord were of the naïve/memory CD38hi CD95lo
phenotype. Nevertheless, they were CD62Llo and CD80hi compared to lymph node B
cells suggesting that they were at least partly activated and primed to present antigen.
Therefore, if meningeal B cells contribute to CNS pathology in autoimmunity, follicular
differentiation is not necessary for the pathogenic mechanism.
Keywords: B cells, EAE, demyelination, inflammation, meninges

Introduction
The best evidence supports the hypothesis that multiple sclerosis (MS) is an autoimmune disease of
the central nervous system (CNS) driven by immune cells targeting myelin antigens. The autoimmune response results in chronic inflammation of the CNS, demyelination, destruction of axons, and
neurodegeneration over an extended period of time (1, 2). The presence of infiltrating immune cells
in MS CNS tissues, including potentially myelin-specific T and B cells, supports a primary immune
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etiology for disease (3–6), as do studies that have identified genes
associated with the immune system, immune regulation, and
antigen presentation as the primary genetic risk factors for MS
(7). Deliberate induction of myelin-targeting autoimmunity in
animal models results in CNS inflammation and pathology that
recapitulates some features of human MS, although the degree to
which these models resemble human disease varies depending
on how autoimmunity is induced and on the species or strain of
animal used (8–10).
Outside of the laboratory, the vast majority of immune
responses incorporate antigen targeting by multiple subpopulations of both T and B cells. However, in recent decades, research
interest has focused heavily on CD4+ T cells and this is particularly
true of MS research. Considerable advances in our understanding of how B cells collaborate with CD4+ T cells during the initiation and development of a response highlight the importance
of understanding immune responses as a whole. When both T
and B cells are involved in target recognition, germinal center
(GC) formation is the typical result. GCs are the source for long
lived, high affinity B cell and antibody responses fundamental
to normal, complex protective, and pathogenic immunity (11).
While best known for their role in antibody production, it is
becoming increasingly apparent that B cells are also important
regulators and modulators of the immune response through the
production of cytokines (12, 13) and presentation of antigen to
T cells (14). As antigen-presenting cells (APCs), B cells very efficiently take up antigen that binds to their specific B cell receptor
(BCR) and process it for presentation to T cells. The resulting
“cognate” interactions between T and B cells specific for the same
or physically linked antigen are foundational to the development
of most complex immune responses (15, 16), almost certainly
including those underlying organ-specific autoimmune diseases
like MS (4).
Considerable evidence supports an important role for B cells
in addition to T cells in driving MS pathology. The presence of
antibodies in the cerebrospinal fluid (CSF) and B cells in the
CNS infiltrate has long been recognized as features of disease
(4, 5). More recently, targeted depletion of CD20-expressing B
cells using humanized anti-CD20 antibodies was shown to very
effectively reduce inflammatory signs and relapses in MS (17).
This ignited interest in B cells as therapeutic targets. However,
a more recent trial of a soluble recombinant version of the
cytokine receptor TACI (TACI-Fc), which depletes B cells
through the inhibition of the cytokines BAFF and APRIL, was
halted early due to indications that treatment increased relapse
rate (18). Anti-CD20 and TACI-Fc deplete B cells through very
different mechanisms and target different subsets of cells (19).
CD20 is not expressed by antibody-producing plasma cells and
therapeutic benefit of anti-CD20 was observed well prior to
any reduction in antibody levels. By contrast, TACI-Fc does
target plasma cells in addition to mature B cells. Further, as
both T cells and neurons express receptors for BAFF (20, 21),
the effects of this drug likely extend well beyond B cell depletion. Therefore, while antibodies may contribute to pathology
(1), the primary B cell contribution to MS is through some
other mechanism(s), perhaps via APC function or cytokine
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modulation of the autoimmune response. Furthermore, the
effectiveness of B cell depletion via anti-CD20 (17) suggests
that their pathogenic role is ongoing and drives chronic
disease. The lack of benefit and perhaps pathogenic effects of
TACI-Fc confuses the issue, and highlights the need to identify
pathogenic and protective B cell subpopulations and their roles
in CNS autoimmunity.
It is also not clear where, anatomically, B cells exert their
pathogenic function. There has been considerable recent interest
in clusters of B and T cells observed in the meninges in postmortem studies of MS brains, often in direct association with
demyelinating lesions (3, 6, 22). Some studies have focused on
the potential similarity of these structures to secondary lymphoid
organs, suggesting that they may perform similar functions in
propagating immune responses from within the inflamed CNS
(23, 24). Understanding the pathogenic contributions of B cells
and the role played by meningeal clusters to ongoing disease will
require models that appropriately recapitulate a complex antimyelin immune response.
Animal models with induced anti-myelin autoimmunity are
referred to by the umbrella term “experimental autoimmune
encephalomyelitis” (EAE). Currently, the most commonly used
versions of this model are induced through immunization with
short peptides mimicking dominant CD4+ T cell epitopes derived
from myelin protein antigens. By their design, these models
severely limit the involvement of other lymphocytes, including
B cells that would normally participate in antigen targeting.
Immunization with larger protein antigens can overcome this
limitation (25). Alternatively, B cells may contribute to several
non-immunization-based models. CNS autoimmunity can
develop “spontaneously” (sEAE) in a proportion of mice with
enhanced anti-myelin activity due to expression of mutant
antigen-specific receptors (26–28). In most cases, enhanced antimyelin immunity is restricted to T cells. However, two groups
(29, 30) independently reported that disease occurs with much
greater incidence in mice expressing both a transgenic T cell
receptor (TCR) specific for myelin oligodendrocyte glycoprotein
(MOG)35–55 peptide (26) and a BCR heavy chain knock-in mice
that, when paired with an appropriate light chain, also confers
specificity for MOG protein on ~20% of B cells (31). This model,
with predetermined B as well as T cell recognition of the myelin
autoantigen, may therefore be valuable for investigations of the
B cell collaboration with autoimmune T cells to promote CNS
autoimmune disease.
Here, we characterize B cells participating in spontaneous
CNS autoimmune disease in 2D2 IgHMOG mice. We observe that
sEAE can follow either a monophasic or chronic disease course
and that this correlates with ongoing inflammation in the spinal
cord and with formation of meningeal clusters of T and B cells in
particular. However, we found little evidence that the B cells in
meningeal clusters are activated in a conventional sense. Finally,
only in a very rare case did we find any evidence of development
of follicular features in meningeal clusters, indicating that if clusters do contribute to ongoing pathology in CNS autoimmunity,
the relatively unorganized form must represent the minimum
requirement for disease.
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Materials and Methods

Life Sciences) gradient. Leukocytes were collected at the 37/90%
Percoll interface.
Both lymph node and isolated spinal cord cell suspensions
were blocked with an anti-Fc-γ receptor (CD16/32 2.4G2) in
PBS containing 1% FBS before further incubation with the listed
combination of staining antibodies. Dead cells were excluded
by staining with the Fixable Viability Dye eFluor506 (eBioscience). Flow cytometry was performed on a LSRII cytometer (BD
Immunocytometry Systems) and analyzed with FlowJo software
(Treestar).

Mice

Wild type C57Bl/6 and 2D2 TCR transgenic (26) mice were
purchased from Jackson Laboratories. IgHMOG MOG-specific
BCR knock-in mice (32) were received as a gift from Dr.
Hartmut Wekerle. Genotyping was accomplished using the following primers: 2D2: f-GCG GCC GCA ATT CCC AGA GAC
ATC CCT CC, r-CCC GGG CAA GGC TCA GCC ATG CTC
CTG; IgHMOG: f-GGA TTG CAC GCA GGT TCT CCG, r-CCG
GCC ACA GTC GAT GAA TCC. All mice were housed under
specific pathogen-free conditions at the West Valley Barrier
Facility at Western University Canada. Animal protocols
(#2011-047) were approved by the Western University Animal
Use Subcommittee.

Immunofluorescent Histology

Spinal cords and lymph nodes were extracted from mice and prepared, as previously described (25). Briefly, whole lymph nodes
and spinal cords were fixed in periodate–lysine–paraformaldehyde (PLP) and subsequently passed through sucrose gradients to
protect from freezing artifacts. Lymph nodes were frozen whole
in OCT (TissueTek) media. Spinal cords were cut into five to nine
evenly spaced pieces and arranged in order prior to freezing in
OCT. Serial cryostat sections (7 μm) were blocked in PBS containing 1% Bovine Serum Albumin, 0.1% Tween-20, and 10% rat
serum before proceeding with staining. Sections were mounted
with ProLong Gold Antifade Reagent (Invitrogen) and stored at
−20°C. Tiled images of whole spinal cord sections (20×) were
imaged using DM5500B fluorescence microscope (Leica).

Antibodies for Flow Cytometry and Histology

The following antibodies were purchased from BD Biosciences:
anti-CD4-V450 (RM4-5), anti-CD45R-V450 (RA3-6B2), antiCD45R-APC-Cy7 (RA3-6B2), anti-CD45R-A647 (RA3-6B2),
anti-CD138-BV421
(281-2),
anti-CD19-BV711
(1D3),
anti-CD95-PE-Cy7 (Jo2), anti-Bcl6-A647 (K112-91), antiIgG1-APC (A85-1), anti-CD62L-A700 (MEL-14), anti-CD35biotin (8C12), anti-CD49D (R1-2), anti-CD62P (RB40.34),
anti-IgM-APC (II/41), and anti-CD80-PE (16-10A1). The following antibodies were purchased from BioLegend: anti-CD4-A647
(RM4-5), anti-CD3e-FITC (145-2C11), and anti-rabbit DyLight
649 (Poly4064). The following antibodies were purchased from
eBioscience: anti-CD4-PE-Cy5 (RM4-5), anti-PNAd-A488
(MECA-79), anti-CD38-PE (90), anti-IgM-PE-Cy5 (II/41),
anti-IgD-APC (11-26c), anti-IgD eF450 (11-26c), anti-CD279Biotin (RMP1-30), anti-CD273-Biotin (TY25), anti-F4/80Biotin (BM8), Streptavidin-APC-eF780, and Streptavidin-APC.
Anti-Ki-67 (SP6) unconjugated was purchased from Thermo
Scientific. FluoroMyelin Red for myelin staining was purchased
from Invitrogen.

Image and Statistical Analyses

The size of meningeal clusters in images of diseased spinal cords
was analyzed using ImageJ software. PRISM software was used for
all statistical analysis. Unless otherwise stated, single comparisons
were performed using a Student’s t-test and multiple comparisons
were performed by ANOVA followed by a Tukey post hoc test.

Results
Disease Incidence in 2D2 IgHMOG Double Mutant
Mice

Spontaneous 2D2 IgHMOG EAE Model

We followed mice bearing mutant TCR and BCR specific for
MOG autoantigen for the development of CNS autoimmune disease. Mice demonstrating overt signs of physical disability were
defined as “sick.” Consistent with the previous descriptions (29, 30,
33), a proportion of unmanipulated 2D2+/− IgHMOG+/+ mice (here
after described as 2D2 IgHMOG) developed sEAE (Figure 1A).
No disease was observed in either 2D2 (TCR) or IgHMOG (BCR)
single mutant mice (Not Shown); it is clearly demonstrating that
antigen recognition by both T and B cells contributes to disease
development in double mutant mice. Interestingly, males were
significantly more likely to develop disease than females, although
there was no difference in the time of onset (Table 1). Although
previous studies did not note gender differences, the incidence
data presented by Krishnamoorthy et al. (30) suggest a similar
trend in male bias.
Overall incidence was highly variable over the study period.
Initially, 39% of unmanipulated mice developed signs of disease
(Figure 1A, Timepoint 1), but over ~2 years of study incidence
fell to 0% (Timepoint 2) but later rose to nearly 100% incidence

2D2+/− IgHMOG+/− double mutant mice were generated as the F1
generation of 2D2+/− mice crossed with IgHMOG+/+ mice. Where
indicated, some mice received a single i.v. injection of 250 ng
pertussis toxin (PTX – List Biological Laboratories, Inc.) between
31 and 33 days of age. Clinical disease was monitored daily and
was scored as follows: 0, no clinical signs; 1, tail paralysis; 2, tail
paralysis and hind limb weakness; 3, hind limb paralysis; and
4, complete hind limb paralysis and front limb weakness. Half
points were given for intermediate scores.

Flow Cytometry

Flow cytometry analysis of T cells and B cells harvested from
mouse lymph nodes and spinal cords was performed, as previously described (25). Briefly, spinal cord and lymph nodes,
including inguinal, axillary, and cervical lymph nodes, were
harvested from mice after perfusion with ice cold PBS. Individual
spinal cords were additionally dissociated through a wire mesh
after which myelin was removed using a Percoll (GE Healthcare
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(Timepoint 3). Season has previously been identified as a factor contributing to susceptibility to EAE in a different induced
model (34), but did not explain the variance observed in the case
of our 2D2 IgHMOG colony. We also excluded obvious changes in
environmental factors, such as food or alterations in animal care.
Differences in animal housing, largely attributed to differences
in microbial exposure, are well known to impact EAE models
and spontaneous models, in particular, both between institutions
and within the same colony (27, 35). We did not investigate commensal bacteria in our own studies, but unexplained changes
in microbiota over time may be the underlying reason for the
dramatic shifts in incidence we observed within our colony.
Nevertheless, this suggests that, like human MS, spontaneous
CNS autoimmune disease in 2D2 IgHMOG mice is variable and
influenced by environmental factors.
Pertussis toxin (PTX) is commonly used in the induction
of several models of immunization-induced EAE, particularly
in C57Bl/6 mice. While the disease-promoting mechanism(s)
are not entirely clear (36–38), PTX represents an antigen nonspecific pathway to promote disease. Indeed, PTX was shown to
increase incidence in a similar model of otherwise spontaneous
CNS autoimmunity that develops in mice expressing a transgenic
TCR to myelin basic protein (27). In our hands, we similarly
found that a single i.v. injection of 250 ng PTX was sufficient to
significantly increase disease incidence in 2D2 IgHMOG mice during periods of lower disease incidence (<80%) (Figures 1B,C).
Disease in PTX-treated mice was otherwise indistinguishable
from that in mice that did not receive PTX (not shown). The
mechanism by which it promotes disease induction is not yet
clear, but we (37) and others (36, 39) have shown that PTX has
innate immunomodulatory effects. Therefore, PTX may act as a
surrogate for environmental factors that promote development of
CNS autoimmune disease.

2D2 IgHMOG Mice Develop Either Monophasic or
Chronic Disease

2D2 IgHMOG mice were evaluated daily for disease severity. Of
those that showed signs of disease (defined as “sick”), the majority
of mice had severe disability of the tail, hindlimbs, and partial
involvement of the forelimbs, reminiscent of other EAE models
and consistent with previous descriptions of this model (29, 30).
Unlike for disease incidence (see above), there was no difference between males and females in maximum disease severity
(Table 1). We observed that disease typically followed one of two
courses; after the initial acute phase some mice largely recovered
with little evidence of ongoing disability while others showed
little sign of recovery. Therefore, we grouped mice that survived
past 21 days post disease onset (i.e., that had not been used
experimentally or been euthanized early due to severe disease)
into one of two groups based on their final disease status: (1)
chronic – mice with no more than 1 point recovery after the
acute phase as determined by the standard 5 point score system,
and 2) Monophasic – mice that recovered at least 1 point on
the severity scale and had a final score <2 (Figure 2). Further
evaluation of these populations showed that while the timing of
disease onset was not different between them, the chronic group
attained a significantly higher maximum disease score (Table 2).

FIGURE 1 | Incidence of spontaneous CNS autoimmune disease
(sEAE) in 2D2 IgHMOG mice. (A) Disease onset curves for three
representative sequential 4- to 6-month time-periods (Timepoint 1, 2,
and 3) selected from the ~2-year period of study. The percent of mice in
each group to demonstrate signs of disability as determined by the
disease scoring system (see Materials and Methods) is shown (% Sick)
(B,C) PTX administration increases disease incidence. (B) Single
injections of 250 ng PTX i.v. were administered to ~32 days old 2D2
IgHMOG mice, which were subsequently followed for onset of disease
compared to unmanipulated mice. (C) Fraction of diseased mice in
PTX-untreated and -treated mice, restricted to times when the overall
incidence was below 80%. Significantly more PTX-treated mice
developed disease as determined by Chi-square analysis (p = 0.0003,
df = 13.13,1).
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TABLE 1 | Disease profiles in 2D2 IgHMOG mice by gender.

Male
Female

n=

Sick

Incidence

Day onset

SEM

Max score

SEM

154
137

95
68*

61.7%
49.6%

36.7
36.6

(±0.52)
(±0.68)n.s.

2.55
2.43

(±0.107)
(±0.143)n.s.

*p = 0.0387, df = 4.275,1 by Chi squared analysis. Note that mice that did not develop disease were not included in analysis of onset and severity.
n.s., not significant.

FIGURE 2 | sEAE in 2D2 IgHMOG mice can follow a monophasic or chronic disease course. (A) 2D2 IgHMOG mice were allowed to develop CNS autoimmune
disease and severity was evaluated daily. Mice that developed signs of CNS autoimmune disease for at least 21 days (excluding mice that had been used
experimentally or were euthanized prior to 21 days) were divided into “monophasic” or “chronic” categories based on the following criteria: chronic – no more than 1
point recovery after the acute phase as determined by the standard 5 point score system. Monophasic – recovery of at least 1 point on the severity scale and a final
score <2. (B) Compared to male mice, a greater proportion of female mice develop chronic disease as determined by Chi-square analysis (p = 0.0004, df 12.65,1).

node atrophy and in some cases little remaining GC response
could be detected (not shown).

TABLE 2 | Monophasic and chronic disease profiles in 2D2 IgHMOG mice.

Monophasic
Chronic

n=

Day onset

SEM

Max score

SEM

42
30

38.2
35.8

(±0.62)
(±1.47)n.s.

2.26
2.98

(±0.117)
(±0.106)***

Evaluation of Spinal Cord Pathology in 2D2
IgHMOG Mice

2D2 IgHMOG mice were sacrificed for histological evaluation of
CNS pathology. No evidence of pathology or inflammation was
evident in the CNS of wild type mice (Figure 4A) or 2D2 IgHMOG
mice that did not develop disease (not shown). Consistent with
previous descriptions of this model (29, 30), there was little
evidence of inflammation in the brains of 2D2 IgHMOG mice that
developed disease (not shown). By contrast, extensive and profound pathology was observed in the spinal cord. Evaluation of
tissue harvested from mice in the acute phase of disease (<11 days
post onset) revealed that extensive infiltration by CD4+ T cells
(Figure 4, compare Figure 4A – wild type to Figure 4B – acute
2D2 IgHMOG) was associated with regions of reduced myelin staining (Figures 4B,C, inset box ii, middle) and F4/80+ macrophage/
activated microglia (Figure 4C, bottom). CD4+ T cells were also
observed in the gray matter in some mice and in these cases
myelin staining of the gray matter was often altered compared to
healthy mice (Figure 4C top, inset box i).
B cell infiltration of the spinal cord was almost exclusively
restricted to the meninges although rare cells could be found in
the white matter lesions. Meningeal B cells often formed clusters
in close association with CD4+ T cells (Figures 4B,C, inset box
ii) reminiscent of lymphoid clusters described in human MS
tissue (3, 6, 22). Similar clusters were also reported in other

***p < 0.001.
n.s., not significant.

This indicates that while the populations were separated into the
chronic or monophasic groups based principally on their status
at the end of the study, the differences between groups manifested
themselves earlier in the acute phase of disease (Figure 2A).
Interestingly, while males were more likely to develop disease
(see above), females were more likely to have a chronic disease
course (Figure 2B).

Characterization of the B Cell Response in 2D2
IgHMOG Mice

Previous studies employing the 2D2 IgHMOG model focused primarily on T cell activation (29, 30, 33) and information about B
cell activation in this or other spontaneous models is very limited.
Immune responses that incorporate both T and B cell recognition of antigen typically result in a GC response. Consistent with
this, significantly more CD95hi CD38lo GC B cells were present
in lymph nodes harvested from sick 2D2 IgHMOG mice (~3 weeks
post onset) compared to wild type or age-matched 2D2 IgHMOG
that did not develop sEAE (Figures 3A,B). It should be noted
that, with disease progression and severity, we observed lymph
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FIGURE 3 | Characterization of B cells in the lymph nodes and spinal cords of 2D2 IgHMOG mice with sEAE. (A) Lymph nodes and spinal cords were
harvested from healthy wild type mice as well as 2D2 IgHMOG mice that had either developed disease (sick – 20–30 days post onset) or not (healthy – age matched).
Cells were prepared and analyzed by FACS. CD45R+ cells were first selected. An example of the gating strategy to identify Plasma cells [(A) – left] and B cells with a
GC phenotype [(A) – right] from the CD45R+ pool is shown for lymph node and spinal cord cells isolated from a single sick mouse. (B) Quantification of CD95hi
CD38lo germinal center B cells in the lymph nodes of wild type and healthy or sick 2D2 IgHMOG mice. Each symbol represents an individual mouse. *p < 0.05. (C)
Comparison of CD62L (left) and CD80 (right) expression by CD45R+ CD19+ CD138− B cells isolated from lymph nodes or the CNS of the same mouse. Each symbol
represents an individual sick mouse. ***p < 0.001 as determined by paired Student’s t-test. One representative of two experiments shown.

investigations of this model (29, 30, 33), indicating that they are
a consistent feature of disease in 2D2 IgHMOG mice. These clusters were very often in direct association with regions of white
matter demyelination and CD4+ T cell infiltration (Figure 4B).
Pathology was not restricted to any particular region of the spinal
cord as in some cases the entire spinal cord was involved, while
in others inflammation was restricted to either distal (lumbar) or
proximal (cervical) regions (not shown).

continued disability in these mice reflects active and ongoing
inflammation, rather than permanent injury incurred during
the initial attack. Large meningeal clusters containing T and
B cells were also common in these mice. Nevertheless, despite
reduced white matter involvement, small meningeal clusters
were sometimes also present in monophasic mice (Figure 5A).
However, subsequent analysis confirmed that meningeal clusters
were both more numerous (Figure 5C) and larger (Figure 5D)
in chronic vs. monophasic mice. Further, independent of disease
course classification the size of meningeal clusters correlated with
disease severity (Figure 5E). This, combined with the common
spatial association between clusters and underlying regions of
demyelination, suggests that these structures may contribute to
ongoing chronic CNS autoimmune disease in 2D2 IgHMOG mice.

B Cell Infiltration of the Spinal Cord is
Associated with Chronic Disease

We next evaluated spinal cord pathology later in disease
(>20 days post disease onset) in mice with either a chronic or
monophasic disease course (as defined above). White matter
pathology in monophasic mice was very limited, in that there
was little CD4+ T cell infiltration or demyelination (Figure 5A).
By contrast, ongoing white and gray matter inflammation by
CD4+ T cells and white matter demyelination was clearly evident
in mice with chronic disease (Figure 5B) demonstrating that
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Clusters

To begin to dissect the role that B cells play in spinal cord
pathology in sEAE, we evaluated the activation phenotype of

6

September 2015 | Volume 6 | Article 470

Dang et al.

B cell inflammation in chronic CNS autoimmunity

FIGURE 4 | Evaluation of spinal cord pathology in 2D2 IgHMOG mice. Mice were sacrificed in the acute phase of disease (<11 days post onset) and spinal cord
pathology was evaluated by immunofluorescent histology. Sections were stained for myelin and invading CD4+ T cells and B220+ B cells. [(A) – wild type health
control, (B) – 2D2 IgHMOG acute disease]. Infiltrating T cells (open triangles) were evident in the gray matter of diseased mice [see (B) inset box i, shown at higher
magnification in (C), top panel]. Clusters containing B220+ B cells and CD4+ T cells (closed triangles) were clearly apparent in the meninges of diseased mice, while
no B cells were found in healthy spinal cords [compare (A) with (B)]. Meningeal clusters were often adjacent to areas of demyelination and CD4+ T cell infiltration of
the white matter (open triangles). Ongoing parenchymal invasion by T cells and macrophages/activated microglia were clearly evident, associated with regions of
demyelination [open triangles, see enlarged image and serial section stained with F4/80, inset box ii, (C)]. Representative images shown (n = 5 wt, n = 5 acute
phase 2D2 IgHMOG, minimum three sections taken from different regions of each spinal cord). Scale bars represent 200 μm.

infiltrating B cells. FACS analysis of lymphocytes isolated from
spinal cords revealed that B cells are almost exclusively CD38hi
CD95lo, consistent with naïve or memory lymph node B cells
(Figure 3A). However, compared to lymph node B cells with a
similar CD38hi CD95lo phenotype, spinal cord B cells had significantly lower expression of CD62L and higher expression of
CD80 (Figure 3C), indicating at least some level of non-classical
activation, perhaps to present antigen. Cluster B cells were further
characterized by histological examination of spinal cord tissue.
We focused on spinal cords from chronic mice (see above) with
evidence of ongoing disease activity. Consistent with a potential
role for B cells in presenting antigen to T cells in clusters, T and
B cells were found in close physical association with each other
(Figures 6A,B). Subsequent staining confirmed that T cells in
clusters were almost exclusively CD4+ T cells. However, we
were surprised to find that CD8+ T cells were minor yet common component of the T cell infiltrate of white and gray matter
(Figure 6A). This was not the case in the acute phase of disease
(not shown). Although CD8+ T cells are known to infiltrate the
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CNS in human MS and contribute to some animal models of CNS
autoimmunity (2, 35), we did not expect their presence in the 2D2
IgHMOG model as the 2D2 TCR is derived from an MHC class
II-restricted CD4+ T cell (26). However, CD8+ T cells were shown
to infiltrate the CNS and participate in pathology in a similar
model that makes use of a different MOG35-55-specific TCR on
the NOD background. Although the TCR in this model was
similarly derived from a CD4+ T cell, CD8+ T cells were found to
express the transgenic TCR and recognize the MOG35–55 peptide
presented on MHC class I (40).
We further investigated cluster B cells for evidence of activation. While Ki67+ cells were detectable within clusters as well as
in the white matter, very few of them were co-stained with B cell
markers (Figure 6B). Instead, the large majority of proliferating Ki67+ cells were T cells (not shown). CD138+ Plasma cells
were not apparent in clusters (Figure 6C). Finally, cluster B
cells were investigated for evidence of class switch. Virtually,
all B cells expressed IgD (Figure 6D) and IgM, but not IgG1
(not shown).

7

September 2015 | Volume 6 | Article 470

Dang et al.

B cell inflammation in chronic CNS autoimmunity

FIGURE 5 | B cell infiltration of the spinal cord is associated with chronic disease and increased disease severity. At study endpoints (~4 weeks post
disease onset), spinal cords were harvested for evaluation of pathology by immunofluorescence histology. Spinal cords from mice deemed to have either a
“Monophasic” (A) or “Chonic” (B) disease course (as defined in Figure 2) were evaluated for demyelination, CD4+ T cell infiltration and meningeal cluster formation.
Solid arrowheads indicate meningeal clusters. Open arrowheads indicate regions of white matter demyelination and infiltration by CD4+ cells. Scale bars represent
200 μm. The number of meningeal clusters per section (C) and cluster area (D) was evaluated using Image J software. Three sections from different regions of the
spinal cord were evaluated from each mouse. **p < 0.01 as determined by Student’s t-test. Each symbol represents the average value per section from an individual
mouse. (E) Cluster size was correlated with average disease score (as a measure of overall disease severity) for each individual mouse included in the study. Each
symbol represents an individual mouse. A two tailed Pearson r test was performed to test for correlation.

It has been suggested that meningeal clusters in the CNS of MS
patients may function as the so-called tertiary lymphoid tissues
that recapitulate the structure and function of secondary lymphoid organs, such as lymph nodes and spleen (22). We therefore
evaluated meningeal clusters in chronic 2D2 IgHMOG mice for features of lymphoid follicles. With the exception of a single cluster
in one mouse from the chronic group (Figure 6E), there was no
evidence that T and B cells were organized into separate zones
as occurs in lymphoid tissue (see Figures 4B, C, 5 and 6A–D for
examples). Neither evidence of CD35+ follicular dendritic cells
(FDCs) (Figure 6F) nor Bcl-6+ staining (GC B cells or T follicular
helper Tfh cells) (not shown) was evident in any cluster that we
examined. Finally, while some evidence of PNAd staining was
apparent in the single cluster with evidence of T and B cell organization (Figure 6F), perhaps indicating development of specialized high endothelial venules, PNAd staining was not evident in
any other cluster that we examined (not shown). Therefore, while
it is possible that given sufficient time a proportion of meningeal
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clusters may attain some features of organized lymphoid tissue,
the majority of clusters remain largely unorganized. If, as their
association with demyelinating regions suggests, these clusters
do contribute to the pathology of CNS autoimmunity, the less
organized form must represent the minimum requirement for the
pathogenic mechanism.

Discussion
Here, we characterize a spontaneous model of CNS autoimmunity that depends on both T and B cell recognition of the
myelin autoantigen. We are aware of only three previously
published studies using this 2D2 IgHMOG model. The original
descriptions came from independent studies from Bettelli et al.
(29) and Krishnamoorthy et al. (30) that focused principally on
characterizing T cell activation as well as lesion distribution,
which they found to be limited to the optic nerve and spinal
cord. A third study made creative use of a version of this model
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FIGURE 6 | Evaluation of meningeal clusters in spinal cords from 2D2 IgHMOG mice with chronic sEAE. Serial sections of spinal cord tissue from mice
determined to have chronic disease (see Figure 2) were stained by immunofluorescence to characterize infiltrating immune cells. Images of one representative
cluster from a single mouse (n = 7) are shown (A–E). Scale bars represent 100 μm. (A) CD3+ CD8+ T cells were a common but minor component of the white
matter infiltrate (open arrowheads), but only very rarely in meningeal clusters. (B) CD4+ cell infiltration into a region of demyelination adjacent to a meningeal cluster
composed of B220+ B cells and CD4+ T cells. Inset box indicates the magnified region shown in subsequent serial sections. (C) Ki67+ cells in cell cycle were evident
in meningeal clusters and in the affected white matter. The large majority of Ki67+ cells did not co-stain with B220 (example – closed arrowhead), with only very rare
exceptions (open circle). (D) Little to no evidence of CD138+ plasma cells was observed in association with meningeal clusters. (E) Nearly, all B220+ B cells in
meningeal clusters co-stained with IgD and therefore not class-switched (gray-scale of IgD channel alone shown on right). (F) Evaluation of meningeal clusters for
evidence of features of lymphoid follicles. (Top) images of the single cluster from a 2D2 IgHMOG mouse with chronic disease to show evidence of T and B cell
organization into different separate regions (left, top – compare to B cell follicle and T cell zone separation in a healthy naïve lymph node, bottom) and differentiation
of specialized high endothelial venules (middle top – compared to extensive PNAd staining in the lymph node, bottom). Little to no evidence of CD35+ follicular
dendritic cells (right, top – compared to extensive follicular staining in the lymph node, bottom) was apparent in this meningeal cluster. For each stain listed above,
between four and seven individual mice with chronic disease were evaluated, choosing sections with the most developed clusters.
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to demonstrate that antibody production by MOG-specific
B cells was not important to disease initiation, which instead
was linked to antigen presentation by B cells to T cells (33). As
discussed in more detail below, our findings presented here are
largely consistent with these previous reports. We extend these
studies by focusing on the B cell response and on characterizing infiltrating B cells and meningeal clusters in the diseased
spinal cord.
The primary goal of our study was to characterize the B cell
response in this B-cell-dependent model of CNS autoimmune
disease. As expected, measurable GC responses were detected in
lymph nodes from sick mice, although this was not true in all
cases due to lymph node atrophy. Nevertheless, a GC response
driven by interactions between MOG-specific T and B cells is presumably the mechanism for B cell-dependent disease initiation,
as B cell presentation of antigen has been shown to be essential in
a similar B cell-dependent mouse model (33). Of greater interest
to therapeutic intervention in autoimmunity is the potential role
of B cells in propagating ongoing disease, which may occur from
within the inflamed CNS. With the exception of the involvement
of CD8+ T cells, which were relatively common infiltrates of the
spinal cord parenchyma in chronic but not acute disease, inflammation and pathology was qualitatively similar over the course
of active disease. We observed extensive B cell infiltration of the
meninges wherever white matter pathology was apparent, often
forming clusters with CD4+ T cells. By contrast, white matter
pathology was largely absent in mice that had recovered from
monophasic disease. It is not clear if this reflects myelin repair
or if extensive demyelination did not occur in these mice and
disability was a reflection of inflammation, rather than actual
tissue destruction.
Contrary to our initial expectations, B cells in meningeal
clusters showed little indication of activation, with no evidence
of class switch and little proliferation compared to infiltrating
CD4+ T cells. By FACS, spinal cord B cells were CD38hi CD95lo,
consistent with naïve or memory cells, although elevated CD80
in particular suggests a degree of activation. Further investigation will be required to determine if B cells upregulate CD80 once
in the meninges or if CD80hi B cells are selectively recruited. It
should be noted that B cell follicles in secondary lymphoid
tissues are largely populated by naïve B cells, and therefore an
unactivated phenotype would be expected if meningeal clusters do indeed represent lymphoid structures. However, with
the possible exception of the single cluster in a mouse with
chronic disease described above, we did not observed any other
evidence of typical follicular features in the meningeal clusters
that formed in sick 2D2 IgHMOG mice. We previously observed
similar clusters in a model of EAE induced by immunization with
a protein antigen based on mouse MOG (25). Again, there was no
evidence of follicular differentiation in these clusters. Together,
these models suggest that cluster formation is common in models
that incorporate B cell recognition of the autoantigen. This is not
an absolute requirement, however, as small clusters could still
form in mice with mutant BCR incapable of recognizing MOG
or in mice immunized with the standard short MOG35–55 peptide
(25). White matter demyelination and inflammation were much
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reduced compared to what we observed in either MOG proteininduced disease or in sick 2D2 IgHMOG mice, which also feature
greater meningeal B cell infiltration.
Models of CNS autoimmunity that incorporate target recognition by more than just CD4+ T cells, such as 2D2 IgHMOG
mice or EAE models induced with protein antigen, represent
significant improvements over peptide-induced models that are
used most commonly today as they allow for a more normal and
complex response. Responses to “real” antigens recruit multiple
immune targeting and effector processes. Nevertheless, it is
not clear that these models more accurately represent human
MS. Focusing specifically on investigations of infiltrating B
cells in MS, lineage analysis suggest that B cells isolated from
CNS represent a population derived from the GC response
and subsequently selected from the peripheral pool (4, 41, 42).
FACS studies suggest that CSF B cells are enriched for CD27+
cells (4, 43, 44), which in humans is considered a marker of
memory. Therefore, these studies suggest that at least some B
cells in human disease were previously activated. As there is no
equivalent memory marker in mice, it is not currently possible
to directly compare these observations to our own of the 2D2
IgHMOG model.
Histological studies of human post-mortem tissue have
been inconsistent in finding meningeal clusters (3, 6, 45–48).
When clusters have been observed (3, 6, 45), more examples
of follicular differentiation were reported than we observed in
our mouse models [here and in Ref. (25)]. Nevertheless, our
observations suggest that, given time, it is possible that meningeal clusters can attain at least some features of true follicles.
Human studies were performed on tissues from patients who
had disease for many years and in most cases decades (22), and
despite their focus on the most follicle-like structures, it is clear
that most meningeal clusters in MS remained largely unorganized (22, 23), consistent with our observations in both mouse
models. Furthermore, human studies were almost exclusively
of progressive disease, where neurodegeneration occurs even
though there is less evidence of active inflammation (2). It is
not clear that these observations are relevant to the earlier active
inflammatory stage of disease that is likely a better correlate to
EAE. The rarity of tissue from this earlier stage of disease and
of spinal cord tissue will make direct comparison very difficult.
Nevertheless, as the best evidence supports the hypothesis that
MS is an autoimmune disease targeting myelin antigens, holistic models of CNS autoimmune disease that more completely
involve the immune system have the best chance of revealing
important fundamental pathogenic B cell mechanisms that
drive ongoing disease.
The apparent contradictory effects of B cell depletion by antiCD20 (17) vs. TACI-Fc (18) in human MS highlights the urgent
need to better understand the complex biology of these cells in
autoimmune disease and the immune response in general. Both
anti-CD20 and TACI-Fc target IL-10-producing Breg cells (19,
49). However, they have very different activity on plasma cells
and therefore antibody production (19), as well as T cell biology
(20). There are likely additional B cell subsets with differential
susceptibility to depletion by each reagent. Indeed, IgM+
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memory B cells are more dependent on BAFF and therefore to
depletion by TACI-Fc than class-switched memory cells (50).
Anatomical location may also affect susceptibility to depletion
by either reagent. Work to decipher this will have to rely heavily
on models, such as the 2D2 IgHMOG mice, as in human patients
usually only the circulating and more rarely CSF pools can
be accessed. Our models suggest that antigen-specific B cells
contribute to disease but that, unexpectedly, the B cell infiltrate
in the CNS are not activated in a way that we would expect
based on studies of antigen-specific activation in lymphatic tissue. Further work will be required to identify subsets of B cells,
how they contribute to pathology or protection from disease,

and their susceptibility to different methods of therapeutic
intervention.

Acknowledgments
The authors would like to thank the animal care staff at the West
Valley Barrier facility for their excellent husbandry. This work was
supported by an operating grant from the Multiple Sclerosis Society
of Canada (#1294). SK was a recipient of the Garrett Herman endMS
Research and Training Network Career Development Award from
the Multiple Sclerosis Society of Canada. RJ is a recipient of a PhD
Studentship from the Multiple Sclerosis Society of Canada.

References
19.

1. Antel J, Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol (2006) 180:3–8.
doi:10.1016/j.jneuroim.2006.06.032
2. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol (2008)
28:29–45. doi:10.1055/s-2007-1019124
3. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al.
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain (2007)
130:1089–104. doi:10.1093/brain/awm038
4. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central
nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol (2006) 59:880–92. doi:10.1002/
ana.20890
5. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald
criteria. Ann Neurol (2011) 69:292–302. doi:10.1002/ana.22366
6. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic
B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol (2004) 14:164–74. doi:10.111
1/j.1750-3639.2004.tb00049.x
7. Sawcer S, Franklin RJM, Ban M. Multiple sclerosis genetics. Lancet Neurol
(2014) 13:700–9. doi:10.1016/S1474-4422(14)70041-9
8. Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol (2007) 7:904–12. doi:10.1038/nri2190
9. Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune
encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol
(2011) 164:1079–106. doi:10.1111/j.1476-5381.2011.01302.x
10. t Hart BA, Laman JD, Bauer J, Blezer E, van Kooyk Y, Hintzen RQ. Modelling
of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol
(2004) 3:588–97. doi:10.1016/S1474-4422(04)00879-8
11. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev (2012) 247:52–63.
doi:10.1111/j.1600-065X.2012.01124.x
12. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell
depletion therapy ameliorates autoimmune disease through ablation of IL-6producing B cells. J Exp Med (2012) 209:1001–10. doi:10.1084/jem.20111675
13. Matsushita T, Yanaba K, Bouaziz J-D, Fujimoto M, Tedder TF. Regulatory
B cells inhibit EAE initiation in mice while other B cells promote disease
progression. J Clin Invest (2008) 118:3420–30. doi:10.1172/JCI36030
14. Chen X, Jensen PE. The role of B lymphocytes as antigen-presenting cells. Arch
Immunol Ther Exp (Warsz) (2008) 56:77–83. doi:10.1007/s00005-008-0014-5
15. Phan TG, Gray EE, Cyster JG. The microanatomy of B cell activation. Curr
Opin Immunol (2009) 21:258–65. doi:10.1016/j.coi.2009.05.006
16. Ramiscal RR, Vinuesa CG. T-cell subsets in the germinal center. Immunol Rev
(2013) 252:146–55. doi:10.1111/imr.12031
17. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies.
Clin Immunol (2012) 142:31–7. doi:10.1016/j.clim.2011.04.005
18. Kappos L, Hartung H-P, Freedman MS, Boyko A, Radü E-W, Mikol DD, et al.
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled,

Frontiers in Immunology | www.frontiersin.org

20.
21.
22.
23.
24.
25.

26.

27.

28.

29.
30.

31.

32.

11

double-blind, phase 2 trial. Lancet Neurol (2014) 13:353–63. doi:10.1016/
S1474-4422(14)70028-6
Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in
multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 8:613–23.
doi:10.1038/nrneurol.2012.203
Croft M. The TNF family in T cell differentiation and function – unanswered questions and future directions. Semin Immunol (2014) 26:183–90.
doi:10.1016/j.smim.2014.02.005
Tada S, Yasui T, Nakatsuji Y, Okuno T, Koda T, Mochizuki H, et al. BAFF controls neural cell survival through BAFF receptor. PLoS One (2013) 8:e70924.
doi:10.1371/journal.pone.0070924
Haugen M, Frederiksen JL, Degn M. B cell follicle-like structures in multiple
sclerosis-with focus on the role of B cell activating factor. J Neuroimmunol
(2014) 273:1–7. doi:10.1016/j.jneuroim.2014.05.010
Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory
diseases. Nat Rev Immunol (2006) 6:205–17. doi:10.1038/nri1786
Ruddle NH. Lymphatic vessels and tertiary lymphoid organs. J Clin Invest
(2014) 124:953–9. doi:10.1172/JCI71611
Dang AK, Jain RW, Craig HC, Kerfoot SM. B cell recognition of myelin
oligodendrocyte glycoprotein autoantigen depends on immunization
with protein rather than short peptide, while B cell invasion of the CNS in
autoimmunity does not. J Neuroimmunol (2015) 278C:73–84. doi:10.1016/j.
jneuroim.2014.12.008
Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin
oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop
spontaneous autoimmune optic neuritis. J Exp Med (2003) 197:1073–81.
doi:10.1084/jem.20021603
Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM.
Transgenic mice that express a myelin basic protein-specific T cell
receptor develop spontaneous autoimmunity. Cell (1993) 72:551–60.
doi:10.1016/0092-8674(93)90074-Z
Pöllinger B, Krishnamoorthy G, Berer K, Lassmann H, Bösl MR, Dunn R,
et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive
transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med (2009)
206:1303–16. doi:10.1084/jem.20090299
Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte
glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in
mice. J Clin Invest (2006) 116:2393–402. doi:10.1172/JCI28334
Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune
T cell/B cell cooperation. J Clin Invest (2006) 116:2385–92. doi:10.1172/
JCI28330
Litzenburger T, Blüthmann H, Morales P, Pham-Dinh D, Dautigny A, Wekerle
H, et al. Development of myelin oligodendrocyte glycoprotein autoreactive
transgenic B lymphocytes: receptor editing in vivo after encounter of a self-
antigen distinct from myelin oligodendrocyte glycoprotein. J Immunol (2000)
165:5360–6. doi:10.4049/jimmunol.165.9.5360
Litzenburger T, Fässler R, Bauer J, Lassmann H, Linington C, Wekerle H,
et al. B lymphocytes producing demyelinating autoantibodies: development
and function in gene-targeted transgenic mice. J Exp Med (1998) 188:169–80.
doi:10.1084/jem.188.1.169

September 2015 | Volume 6 | Article 470

Dang et al.

B cell inflammation in chronic CNS autoimmunity

33. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod’homme
T, Varrin-Doyer M, et al. MHC class II-dependent B cell APC function is
required for induction of CNS autoimmunity independent of myelin-specific
antibodies. J Exp Med (2013) 210:2921–37. doi:10.1084/jem.20130699
34. Teuscher C, Bunn JY, Fillmore PD, Butterfield RJ, Zachary JF, Blankenhorn EP.
Gender, age, and season at immunization uniquely influence the genetic control
of susceptibility to histopathological lesions and clinical signs of experimental
allergic encephalomyelitis: implications for the genetics of multiple sclerosis.
Am J Pathol (2004) 165:1593–602. doi:10.1016/S0002-9440(10)63416-5
35. Simmons SB, Pierson ER, Lee SY, Goverman JM. Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol (2013) 34:410–22.
doi:10.1016/j.it.2013.04.006
36. Fujimoto C, Yu C-R, Shi G, Vistica BP, Wawrousek EF, Klinman DM, et al.
Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells
and their cytokine production. J Immunol (2006) 177:6896–903. doi:10.4049/
jimmunol.177.10.6896
37. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, Zanardo
RCO, et al. TLR4 contributes to disease-inducing mechanisms resulting in
central nervous system autoimmune disease. J Immunol (2004) 173:7070–7.
doi:10.4049/jimmunol.173.11.7070
38. Linthicum DS, Munoz JJ, Blaskett A. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive
amine sensitization and increased vascular permeability of the central nervous
system. Cell Immunol (1982) 73:299–310. doi:10.1016/0008-8749(82)90457-9
39. Zhou H, Wang Y, Lian Q, Yang B, Ma Y, Wu X, et al. Differential IL-10 production by DCs determines the distinct adjuvant effects of LPS and PTX in EAE
induction. Eur J Immunol (2014) 44:1352–62. doi:10.1002/eji.201343744
40. Anderson AC, Chandwaskar R, Lee DH, Sullivan JM, Solomon A, RodriguezManzanet R, et al. A transgenic model of central nervous system autoimmunity
mediated by CD4+ and CD8+ T and B cells. J Immunol (2012) 188:2084–92.
doi:10.4049/jimmunol.1102186
41. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al.
Related B cell clones populate the meninges and parenchyma of patients with
multiple sclerosis. Brain (2011) 134:534–41. doi:10.1093/brain/awq350
42. Stern JNH, Yaari G, Vander Heiden JA, Church G, Donahue WF, Hintzen
RQ, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med (2014) 6:248ra107. doi:10.1126/
scitranslmed.3008879

Frontiers in Immunology | www.frontiersin.org

43. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived
plasma blasts are the main B cell effector subset during the course of multiple
sclerosis. Brain (2005) 128:1667–76. doi:10.1093/brain/awh486
44. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, et al.
Recapitulation of B cell differentiation in the central nervous system of
patients with multiple sclerosis. Proc Natl Acad Sci U S A (2004) 101:11064–9.
doi:10.1073/pnas.0402455101
45. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM,
et al. Meningeal inflammation is widespread and linked to cortical pathology
in multiple sclerosis. Brain (2011) 134:2755–71. doi:10.1093/brain/awr182
46. Kooi E-J, Geurts JJG, van Horssen J, Bø L, van der Valk P. Meningeal
inflammation is not associated with cortical demyelination in chronic
multiple sclerosis. J Neuropathol Exp Neurol (2009) 68:1021–8. doi:10.1097/
NEN.0b013e3181b4bf8f
47. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al.
A gradient of neuronal loss and meningeal inflammation in multiple sclerosis.
Ann Neurol (2010) 68:477–93. doi:10.1002/ana.22230
48. Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R,
et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory
cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp
Neurol (2013) 72:29–41. doi:10.1097/NEN.0b013e31827bfc62
49. Yang M, Sun L, Wang S, Ko K-H, Xu H, Zheng B-J, et al. Novel function of B
cell-activating factor in the induction of IL-10-producing regulatory B cells.
J Immunol (2010) 184:3321–5. doi:10.4049/jimmunol.0902551
50. Scholz JL, Crowley JE, Tomayko MM, Steinel N, O’Neill PJ, Quinn WJ, et al.
BLyS inhibition eliminates primary B cells but leaves natural and acquired
humoral immunity intact. Proc Natl Acad Sci U S A (2008) 105:15517–22.
doi:10.1073/pnas.0807841105
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Dang, Tesfagiorgis, Jain, Craig and Kerfoot. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.

12

September 2015 | Volume 6 | Article 470

